BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naoumov NV. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol. 2014;61:1166-1174. [PMID: 25048953 DOI: 10.1016/j.jhep.2014.07.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Soares ROS, Losada DM, Jordani MC, Évora P, Castro-E-Silva O. Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies. Int J Mol Sci 2019;20:E5034. [PMID: 31614478 DOI: 10.3390/ijms20205034] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
2 Jiang J, Yin H, Sun Y, Huang H, Hu X. Clonorchis sinensis cyclophilin A immunization protected mice from CLP-induced sepsis. International Immunopharmacology 2018;59:347-53. [DOI: 10.1016/j.intimp.2018.03.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLoS One. 2015;10:e0134707. [PMID: 26263487 DOI: 10.1371/journal.pone.0134707] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
4 Steadman VA, Pettit SB, Poullennec KG, Lazarides L, Keats AJ, Dean DK, Stanway SJ, Austin CA, Sanvoisin JA, Watt GM, Fliri HG, Liclican AC, Jin D, Wong MH, Leavitt SA, Lee Y, Tian Y, Frey CR, Appleby TC, Schmitz U, Jansa P, Mackman RL, Schultz BE. Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A. J Med Chem 2017;60:1000-17. [DOI: 10.1021/acs.jmedchem.6b01329] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
5 Simón Serrano S, Tavecchio M, Grönberg A, Sime W, Jemaà M, Moss S, Gregory MA, Gallay P, Elmér E, Hansson MJ, Massoumi R. Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3041. [PMID: 34207224 DOI: 10.3390/cancers13123041] [Reference Citation Analysis]
6 Zhao S, Liu J, Guan G, Liu A, Li Y, Yin H, Luo J. Theileria annulata Cyclophilin1 (TaCyp1) Interacts With Host Cell MED21. Front Microbiol 2018;9:2973. [PMID: 30559736 DOI: 10.3389/fmicb.2018.02973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
8 Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015;42:829-844. [PMID: 26238707 DOI: 10.1111/apt.13342] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
9 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
10 Li J, Kovackova S, Pu S, Rozenski J, De Jonghe S, Einav S, Herdewijn P. Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase : synthesis, structure-activity relationship studies and antiviral activity. Medchemcomm 2015;6:1666-72. [PMID: 26925208 DOI: 10.1039/c5md00229j] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
11 Puengel T, Liu H, Guillot A, Heymann F, Tacke F, Peiseler M. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:2668. [PMID: 35269812 DOI: 10.3390/ijms23052668] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
12 Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. J Pharmacol Exp Ther 2019;371:231-41. [PMID: 31406003 DOI: 10.1124/jpet.119.261099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
13 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
14 Naguib M, Abou Elfotouh M, Wifi MN. Elevated Serum Cyclophilin D Level is Associated with Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients with Diabetes Mellitus. Int J Gen Med 2021;14:4665-75. [PMID: 34434058 DOI: 10.2147/IJGM.S322986] [Reference Citation Analysis]
15 Li J, Chen C, Wong G, Dong W, Zheng W, Li Y, Sun L, Zhang L, Gao GF, Bi Y, Liu W. Cyclophilin A protects mice against infection by influenza A virus. Sci Rep 2016;6:28978. [PMID: 27354005 DOI: 10.1038/srep28978] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
16 Sheng C, Yao C, Wang Z, Chen H, Zhao Y, Xu D, Huang H, Huang W, Chen S. Cyclophilin J limits inflammation through the blockage of ubiquitin chain sensing. Nat Commun 2018;9:4381. [PMID: 30348973 DOI: 10.1038/s41467-018-06756-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. World J Hepatol 2015; 7(5): 777-786 [PMID: 25914778 DOI: 10.4254/wjh.v7.i5.777] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 5.1] [Reference Citation Analysis]
18 Ulagesan S, Choi JW, Nam TJ, Choi YH. Peptidyl-prolyl isomerase and the biological activities of recombinant protein cyclophilin from Pyropia yezoensis (PyCyp). Protein Expr Purif 2020;172:105636. [PMID: 32272150 DOI: 10.1016/j.pep.2020.105636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
19 Garg JP, Vucic D. Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases. Semin Nephrol 2016;36:153-61. [PMID: 27339381 DOI: 10.1016/j.semnephrol.2016.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
20 de Wilde AH, Pham U, Posthuma CC, Snijder EJ. Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology 2018;522:46-55. [PMID: 30014857 DOI: 10.1016/j.virol.2018.06.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
21 Radi ZA, Stewart ZS, O'Neil SP. Accidental and Programmed Cell Death in Investigative and Toxicologic Pathology. Curr Protoc Toxicol 2018;76:e51. [PMID: 30040239 DOI: 10.1002/cptx.51] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Klawitter J, Klawitter J, Pennington A, Kirkpatrick B, Roda G, Kotecha NC, Thurman JM, Christians U. Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress. American Journal of Physiology-Renal Physiology 2019;317:F683-94. [DOI: 10.1152/ajprenal.00417.2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Ure DR, Trepanier DJ, Mayo PR, Foster RT. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 2020;29:163-78. [DOI: 10.1080/13543784.2020.1703948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Biasutto L, Azzolini M, Szabò I, Zoratti M. The mitochondrial permeability transition pore in AD 2016: An update. Biochim Biophys Acta 2016;1863:2515-30. [PMID: 26902508 DOI: 10.1016/j.bbamcr.2016.02.012] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 13.0] [Reference Citation Analysis]
25 Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in Development for Hepatitis B. Drugs 2017;77:1263-80. [PMID: 28660478 DOI: 10.1007/s40265-017-0769-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
26 Mao M, Yu X, Ge X, Gu R, Li Q, Song S, Zheng X, Shen T, Li X, Fu Y, Li J, Zhu D. Acetylated cyclophilin A is a major mediator in hypoxia-induced autophagy and pulmonary vascular angiogenesis. J Hypertens 2017;35:798-809. [PMID: 28079595 DOI: 10.1097/HJH.0000000000001224] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
27 Jang HS, Noh MR, Ha L, Kim J, Padanilam BJ. Proximal tubule cyclophilin D mediates kidney fibrogenesis in obstructive nephropathy. Am J Physiol Renal Physiol 2021;321:F431-42. [PMID: 34396791 DOI: 10.1152/ajprenal.00171.2021] [Reference Citation Analysis]
28 Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV; VITAL-1 study team. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology 2015;62:1013-23. [PMID: 26118427 DOI: 10.1002/hep.27960] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
29 Davila J, Levin S, Radi Z. Cell Injury and Necrosis. Comprehensive Toxicology. Elsevier; 2018. pp. 404-53. [DOI: 10.1016/b978-0-12-801238-3.64220-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res 2020;173:104620. [PMID: 31634494 DOI: 10.1016/j.antiviral.2019.104620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
31 Mohebbi A, Mirarab A, Shaddel R, Shafaei Fallah M, Memarian A; Stem Cell Research Center, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran, Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran, Student Research Committee, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran, Department of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran, Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran. Molecular Dynamic Simulation and Docking of Cyclophilin A Mutants with its Potential Inhibitors. jcbr 2021;5:26-41. [DOI: 10.52547/jcbr.5.2.26] [Reference Citation Analysis]
32 Mukherjee R, Mareninova OA, Odinokova IV, Huang W, Murphy J, Chvanov M, Javed MA, Wen L, Booth DM, Cane MC, Awais M, Gavillet B, Pruss RM, Schaller S, Molkentin JD, Tepikin AV, Petersen OH, Pandol SJ, Gukovsky I, Criddle DN, Gukovskaya AS, Sutton R; NIHR Pancreas Biomedical Research Unit. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. Gut 2016;65:1333-46. [PMID: 26071131 DOI: 10.1136/gutjnl-2014-308553] [Cited by in Crossref: 113] [Cited by in F6Publishing: 98] [Article Influence: 18.8] [Reference Citation Analysis]
33 Hayes CN, Chayama K. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Rev Clin Pharmacol 2017;10:583-94. [PMID: 28374641 DOI: 10.1080/17512433.2017.1313111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
34 de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture. Virology 2018;517:148-56. [PMID: 29249267 DOI: 10.1016/j.virol.2017.11.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
35 Seal S, Polley S, Sau S. A staphylococcal cyclophilin carries a single domain and unfolds via the formation of an intermediate that preserves cyclosporin A binding activity. PLoS One 2019;14:e0210771. [PMID: 30925148 DOI: 10.1371/journal.pone.0210771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
36 Vu LT, Orbach SM, Ray WK, Cassin ME, Rajagopalan P, Helm RF. The hepatocyte proteome in organotypic rat liver models and the influence of the local microenvironment. Proteome Sci 2016;15:12. [PMID: 28649179 DOI: 10.1186/s12953-017-0120-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Pan J, Ou Z, Cai C, Li P, Gong J, Ruan XZ, He K. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release. Cell Immunol. 2018;332:111-120. [PMID: 30103942 DOI: 10.1016/j.cellimm.2018.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
38 [DOI: 10.1101/2020.06.19.161042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
39 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
40 Zeisel MB, Crouchet E, Baumert TF, Schuster C. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses 2015;7:5659-85. [PMID: 26540069 DOI: 10.3390/v7112898] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
41 Katwal G, Baral D, Fan X, Weiyang H, Zhang X, Ling L, Xiong Y, Ye Q, Wang Y. SIRT3 a Major Player in Attenuation of Hepatic Ischemia-Reperfusion Injury by Reducing ROS via Its Downstream Mediators: SOD2, CYP-D, and HIF-1α. Oxid Med Cell Longev 2018;2018:2976957. [PMID: 30538800 DOI: 10.1155/2018/2976957] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
42 Hawner M, Ducho C. Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules. Molecules 2020;25:E5963. [PMID: 33339365 DOI: 10.3390/molecules25245963] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
44 Li C, Zhou X, Zhong Y, Li C, Dong A, He Z, Zhang S, Wang B. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease. J Immunol 2016;196:1721-31. [PMID: 26792805 DOI: 10.4049/jimmunol.1502103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
45 Nabi SU, Khan A, Siddiqui EM, Rehman MU, Alshahrani S, Arafah A, Mehan S, Alsaffar RM, Alexiou A, Shen B, Ciobica A. Mechanisms of Mitochondrial Malfunction in Alzheimer’s Disease: New Therapeutic Hope. Oxidative Medicine and Cellular Longevity 2022;2022:1-28. [DOI: 10.1155/2022/4759963] [Reference Citation Analysis]
46 Xin S, Du S, Liu L, Xie Y, Zuo L, Yang J, Hu J, Yue W, Zhang J, Cao P, Zhu F, Lu J. Epstein-Barr Virus Nuclear Antigen 1 Recruits Cyclophilin A to Facilitate the Replication of Viral DNA Genome. Front Microbiol 2019;10:2879. [PMID: 31921057 DOI: 10.3389/fmicb.2019.02879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Banerjee S, Ghoshal S, Stevens JR, McCommis KS, Gao S, Castro-Sepulveda M, Mizgier ML, Girardet C, Kumar KG, Galgani JE, Niehoff ML, Farr SA, Zhang J, Butler AA. Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction. J Biol Chem 2020;295:13753-68. [PMID: 32727846 DOI: 10.1074/jbc.RA120.014381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Rostam MA, Piva TJ, Rezaei HB, Kamato D, Little PJ, Zheng W, Osman N. Peptidyl-prolyl isomerases: functionality and potential therapeutic targets in cardiovascular disease. Clin Exp Pharmacol Physiol 2015;42:117-24. [PMID: 25377120 DOI: 10.1111/1440-1681.12335] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
49 Gomez Marti JL, Wells A, Brufsky AM. Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. J Med Virol 2021;93:2396-405. [PMID: 33331649 DOI: 10.1002/jmv.26743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Petersen OH, Gerasimenko JV, Gerasimenko OV, Gryshchenko O, Peng S. The roles of calcium and ATP in the physiology and pathology of the exocrine pancreas. Physiol Rev 2021;101:1691-744. [PMID: 33949875 DOI: 10.1152/physrev.00003.2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Jang HS, Noh MR, Jung EM, Kim WY, Southekal S, Guda C, Foster KW, Oupicky D, Ferrer FA, Padanilam BJ. Proximal tubule cyclophilin D regulates fatty acid oxidation in cisplatin-induced acute kidney injury. Kidney Int 2020;97:327-39. [PMID: 31733829 DOI: 10.1016/j.kint.2019.08.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
52 Tur J, Farrera C, Sánchez-Tilló E, Vico T, Guerrero-Gonzalez P, Fernandez-Elorduy A, Lloberas J, Celada A. Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK. Immunobiology 2021;226:152114. [PMID: 34303919 DOI: 10.1016/j.imbio.2021.152114] [Reference Citation Analysis]
53 Fonai F, Priber JK, Jakus PB, Kalman N, Antus C, Pollak E, Karsai G, Tretter L, Sumegi B, Veres B. Lack of cyclophilin D protects against the development of acute lung injury in endotoxemia. Biochim Biophys Acta 2015;1852:2563-73. [PMID: 26385159 DOI: 10.1016/j.bbadis.2015.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
54 Li P, Wang X, Zhao M, Song R, Zhao KS. Polydatin protects hepatocytes against mitochondrial injury in acute severe hemorrhagic shock via SIRT1-SOD2 pathway. Expert Opin Ther Targets 2015;19:997-1010. [PMID: 26073907 DOI: 10.1517/14728222.2015.1054806] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
55 Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056. [PMID: 32835213 DOI: 10.1016/j.medidd.2020.100056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
56 Mackman RL, Steadman VA, Dean DK, Jansa P, Poullennec KG, Appleby T, Austin C, Blakemore CA, Cai R, Cannizzaro C, Chin G, Chiva JC, Dunbar NA, Fliri H, Highton AJ, Hui H, Ji M, Jin H, Karki K, Keats AJ, Lazarides L, Lee YJ, Liclican A, Mish M, Murray B, Pettit SB, Pyun P, Sangi M, Santos R, Sanvoisin J, Schmitz U, Schrier A, Siegel D, Sperandio D, Stepan G, Tian Y, Watt GM, Yang H, Schultz BE. Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle. J Med Chem 2018;61:9473-99. [PMID: 30074795 DOI: 10.1021/acs.jmedchem.8b00802] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
57 Zhu W, Lin Y, Liao H, Wang Y. Selection of reference genes for gene expression studies related to intramuscular fat deposition in Capra hircus skeletal muscle. PLoS One 2015;10:e0121280. [PMID: 25794179 DOI: 10.1371/journal.pone.0121280] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
58 Asim M, Sarath Babu V, Qin Z, Zhao L, Su J, Li J, Tu J, Kou H, Lin L. Inhibition of Cyclophilin A on the replication of red spotted grouper nervous necrosis virus associates with multiple pro-inflammatory factors. Fish Shellfish Immunol 2019;92:172-80. [PMID: 31176008 DOI: 10.1016/j.fsi.2019.05.064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
59 Hughes HY, Henderson DK. Postexposure prophylaxis after hepatitis C occupational exposure in the interferon-free era. Curr Opin Infect Dis 2016;29:373-80. [PMID: 27306563 DOI: 10.1097/QCO.0000000000000281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
60 Chatterji U, Bobardt M, Tai A, Wood M, Gallay PA. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother. 2015;59:2496-2507. [PMID: 25666154 DOI: 10.1128/aac.04958-14] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
61 Chen J, Li N, Lian P, Wang J, Li P, Gong Z, Jiang L. Interaction of cyclophilin A with a novel binding protein, SR-25, and characterization of their expression pattern in Chinese hepatocellular carcinoma patients. Oncol Lett 2016;12:5254-60. [PMID: 28105234 DOI: 10.3892/ol.2016.5357] [Reference Citation Analysis]
62 Krocker JD, Lee KH, Henriksen HH, Wang YW, Schoof EM, Karvelsson ST, Rolfsson Ó, Johansson PI, Pedroza C, Wade CE. Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma. Int J Mol Sci 2022;23:6213. [PMID: 35682894 DOI: 10.3390/ijms23116213] [Reference Citation Analysis]
63 de Wilde AH, Boomaars-van der Zanden AL, de Jong AWM, Bárcena M, Snijder EJ, Posthuma CC. Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors. J Virol 2019;93:e00490-19. [PMID: 31243130 DOI: 10.1128/JVI.00490-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Stanciu C, Trifan A, Muzica C, Sfarti C. Efficacy and safety of alisporivir for the treatment of hepatitis C infection. Expert Opin Pharmacother 2019;20:379-84. [PMID: 30576256 DOI: 10.1080/14656566.2018.1560424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
65 Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF. Host-targeting therapies for hepatitis C virus infection: current developments and future applications. Therap Adv Gastroenterol 2018;11:1756284818759483. [PMID: 29619090 DOI: 10.1177/1756284818759483] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
66 Esser-Nobis K, Schmidt J, Nitschke K, Neumann-Haefelin C, Thimme R, Lohmann V. The cyclophilin-inhibitor alisporivir stimulates antigen presentation thereby promoting antigen-specific CD8(+) T cell activation. J Hepatol 2016;64:1305-14. [PMID: 26921685 DOI: 10.1016/j.jhep.2016.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Kozu K, Satoh K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Shimizu T, Sato H, Konno R, Terui Y, Nochioka K, Kikuchi N, Satoh T, Sugimura K, Miyata S, Shimokawa H. Cyclophilin A as a biomarker for the therapeutic effect of balloon angioplasty in chronic thromboembolic pulmonary hypertension. Journal of Cardiology 2020;75:415-23. [DOI: 10.1016/j.jjcc.2019.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]